

1 **Secretome derived from different cell lines in bovine embryo production *in vitro***

2

3 Perrini C<sup>1,2</sup>, Esposti P<sup>2</sup>, Cremonesi F<sup>1,2</sup>, Lange Consiglio A<sup>2\*</sup>

4

5 Perrini C.<sup>1</sup>: Department of Veterinary Medicine, Università degli Studi di Milano, Via Celoria 10,  
6 20133 Milano, Italy. phone n.: +390250331150; fax: +390250331115; <sup>2</sup>Reproduction Unit, Large  
7 Animal Hospital, Via dell'Università 6, 26900 Lodi, Italy. E-mail: [claudia.perrini@unimi.it](mailto:claudia.perrini@unimi.it); phone  
8 n.: +390250331150; fax: +390250331115

9 Esposti P.<sup>2</sup>: Department of Veterinary Medicine, Università degli Studi di Milano, Via Celoria 10,  
10 20133 Milano, Italy. phone n.: +390250331150; fax: +390250331115; <sup>2</sup>Reproduction Unit, Large  
11 Animal Hospital, Via dell'Università 6, 26900 Lodi, Italy. E-mail: [paolaesposti.dvm@gmail.com](mailto:paolaesposti.dvm@gmail.com);  
12 phone n.: +390250331150; fax: +390250331115

13 Cremonesi F.<sup>1</sup>: Department of Veterinary Medicine, Università degli Studi di Milano, Via Celoria  
14 10, 20133 Milano, Italy. phone n.: +390250318146; fax: +390250318148; <sup>2</sup>Reproduction Unit,  
15 Centro Clinico-Veterinario e Zootecnico Sperimentale di Ateneo, Università degli Studi di Milano,  
16 Via dell'Università 6, 26900 Lodi, Italy. E-mail: [fausto.cremonesi@unimi.it](mailto:fausto.cremonesi@unimi.it); phone n.:  
17 +390250331150; fax: +390250331115..

18 Lange-Consiglio A.<sup>1</sup>: Reproduction Unit, Centro Clinico-Veterinario e Zootecnico Sperimentale di  
19 Ateneo, Università degli Studi di Milano, Via dell'Università 6, 26900 Lodi, Italy., Italy. E-mail:  
20 [anna.langeconsiglio@unimi.it](mailto:anna.langeconsiglio@unimi.it); phone n.: +390250331150; fax: +390250331115

21

22 **Running Title:** Secretome and *in vitro* embryo production

23 **Funding information**

24 This study was supported by grants from Università degli Studi di Milano, Milano Italy.

25

26 \*Correspondence should be addressed to Anna Lange-Consiglio, Reproduction Unit, Large Animal

27 Hospital, Università degli Studi di Milano, Italy; E-mail: [anna.langeconsiglio@unimi.it](mailto:anna.langeconsiglio@unimi.it)

28

## 29 ABSTRACT

30 The effect of the conditioned medium (CM), composed of microvesicles (MVs) and soluble factors  
31 present in the supernatant (SN), of bovine endometrial and amniotic cells on embryo quality and  
32 rate of production was investigated. Presumptive zygotes were randomly assigned on day 1, 3 and 5  
33 post fertilization in SOFaa (control, CTR) or in the same medium supplemented with 20%  
34 endometrial or amniotic CM or 20% SN or  $100 \times 10^6$  MVs/mL. Embryos were evaluated on day 7.  
35 On day 1, embryos developed in MVs in both cell lines but at a lower rate than in CTR. On day 3,  
36 amniotic and endometrial CM and MVs produced blastocysts, but the rate of production in CM was  
37 statistically lower than that obtained by MVs in both cell lines. On day 5, embryos were produced  
38 by all the secretome fractions of both cell lines but only amniotic MVs produced embryos at a rate  
39 comparable to CTR. Qualitatively, only amniotic CM and MVs on day 5 provided inner cell mass  
40 values statistically higher than CTR. These data were confirmed by evaluation of genes involved in  
41 apoptosis and reactive oxygen species protection. In conclusion, only amniotic MVs gave results  
42 better than CTR.

43

44 **Key words:** embryo quality, microvesicles, conditioned *medium*, amniotic cells, endometrial cells

45

## 46 INTRODUCTION

47 As already stated, embryos produced *in vitro* are generally of poorer quality compared to those  
48 developing *in vivo* (Wrenzycki and Stinshoff, 2013). The embryo conceived *in vitro* is manipulated  
49 and cultured in very different conditions and many factors involved in this technique, such as  
50 superovulation, characteristics of female and male gametes, *medium* of embryo culture and the  
51 absence of maternal embryo-communication, can influence the quality of *in vitro* embryo (Ventura-  
52 Junca et al. 2015). In cattle, it has been suggested that the absence of these maternal-embryo signals  
53 could be an important cause of the low efficiency of *in vitro* fertilization (IVF) (Thatcher et al.  
54 2001; Ventura-Junca et al. 2015).

55 To mimic the *in vivo* cross-talk environment and to improve the *in vitro* development of embryos,  
56 co-culture systems with somatic cells are widely used in *in vitro* embryo production (IVP) in many  
57 species (White et al. 1989; Rexroad and Powell 1993; Park et al. 2000; Li et al. 2001). Indeed, a co-  
58 culture system with bovine oviduct epithelial cells, to produce bovine *in vitro* zygotes, enhanced  
59 blastocyst formation, the quality of the resulting embryos, and induced specific transcriptomic  
60 changes (Schmaltz-Panneau et al. 2015). This suggests that paracrine mechanisms of  
61 communication between monolayer cells (“helper” cells) and embryos exist. In fact, a variety of  
62 growth factors, receptors and binding proteins are secreted, not only by cells in the *medium*, but also  
63 by the embryos themselves (Van Langendonckt et al. 1996; Izquierdo et al. 1999). This *medium*,  
64 called conditioned media (CM), is composed of factors secreted by cells during culture and it is  
65 cell-free. The CM, produced by culturing granulosa, cumulus or oviductal cells, is used in bovine  
66 embryo IVP and has similar properties in embryonic development to effects produced by co-culture  
67 systems (Rieger et al. 1995). Recent studies have identified the existence of MVs released by cells  
68 into the extracellular environment (Ratajczak et al. 2006; Camussi et al. 2010). Thus, CM can be  
69 defined as a composition of soluble factors plus MVs. These MVs have been shown to contain  
70 proteins, lipids (specifically high levels of sphingomyelins), a variety of RNA species, including  
71 microRNAs (miRNAs) and mRNA fragments (They et al. 2009). The MVs could serve as vehicles  
72 for the transfer of these molecules (Zhang et al. 2009; Raposo and Stoorvogel 2013; Machatinger et  
73 al. 2016). Many studies demonstrated that MVs are secreted by most cells and can be found in  
74 organic fluids such as, for example, in the uterine luminal fluid of cycling and pregnant sheep  
75 (Burns et al. 2014; Machatinger et al. 2016). These findings suggest that these MVs have a  
76 biological role in the interaction between the embryo and the microenvironments that, *in vivo* is  
77 represented by endometrium (Machatinger et al. 2016) and, *in vitro* by different culture conditions.  
78 The *in vitro* use of feeder cells or CM probably provides the MVs required for this cross talk. The  
79 effect of different components of feeder cell secretome has not been investigated and, since it is  
80 difficult to study these communications *in vivo*, we tested these interactions *in vitro*. Endometrium

81 and amnion have a role in the establishment of pregnancy. Endometrial cells were studied at the  
82 early luteal phase because only in this phase (up to the blastocyst stage) are these cells in contact  
83 with the early embryo *in vivo*. The amnion was chosen because Lange-Consiglio et al. (2010) used  
84 the monolayer of equine amniotic progenitor epithelial cells as feeder cells to culture bovine  
85 embryos and showed an increase in blastocyst rate compared to bone marrow derived cells and  
86 control cells, represented by monolayer of cumulus cells. These authors suggested that EGF,  
87 produced by amniotic epithelial cells, may have a positive role on embryonic development. Indeed,  
88 EGF is produced *in vivo* by the endometrial cells and the embryo possesses receptors for it (Pohland  
89 and Tiemann, 1994; Lonergan et al. 1996). In this study, we compared the effects of the secretome  
90 from amniotic progenitor cells and endometrial cells. The secretomes, composed of CM *in toto*, or  
91 MVs or supernatant (SN), collected after removal of MVs, were investigated to identify which of  
92 these components had demonstrable effects on embryo production, in terms of blastocyst quality  
93 and formation rate.

94

## 95 **MATERIALS AND METHODS**

96 Chemicals were obtained from Sigma-Aldrich Chemical (Milan, Italy) unless stated otherwise, and  
97 tissue culture plastic dishes were purchased from Euroclone (Milan, Italy).

98 Samples of endometrial tissue and ovaries were collected from cows slaughtered in a  
99 slaughterhouse (INALCA, Ospedaletto Lodigiano, Lodi, Italy) under national food hygiene  
100 regulations.

101 Allanto-amniotic membranes were obtained at term of normal pregnancies and parturitions from  
102 three cows (*Bos taurus*). All procedures were performed according to approved animal care and use  
103 protocols of the institutional ethics committee and to good veterinary practice for animal welfare as  
104 to European directive 2010/63/UE. Moreover, written consent was obtained from farmers at the  
105 beginning of the study.

106

## 107 **Cell isolation and culture**

108 Portions of allanto-amnion were kept at 4°C in phosphate-buffered saline (PBS; EuroClone, Milan,  
109 Italy) with 100 U/mL penicillin-100 mg/mL streptomycin and amphotericin B and were processed  
110 within 12 h. The amniotic membrane was stripped from the overlying allantois and cut into small  
111 pieces (about 9 cm<sup>2</sup> each) before enzymatic digestion.

112 Amniotic progenitor epithelial derived cells (AMCs) were isolated and characterized as previously  
113 reported (Corradetti et al. 2013). Briefly, amnion fragments were digested with 0.05%  
114 trypsin/EDTA for 45 min at 38.5°C for approximately 45 min. Then, the amnion fragments were  
115 removed and mobilized cells were passed through a 100 µm cell strainer before being collected by  
116 centrifugation at 250 x g for 10 min.

117 Epithelial endometrial cells (EDCs) at early luteal phase (day 4-8, considering day 0 = estrus) were  
118 isolated according to Donofrio et al. (2008). Pieces of endometrium deep 1 mm, large 5 mm and  
119 long 10 mm were collected (overall 3.5 g). These pieces were deeply cut with scissors and digested  
120 in sterile filtered Hank's buffered salt solution supplemented with 2 mg/mL collagenase II, 2  
121 mg/mL trypsin III (Roche), 4 mg/mL bovine serum albumin, and 0.4 mg/mL DNase I for 90  
122 minutes at 38.5°C in a shaking bath. To obtain separate stromal and epithelial cell populations, the  
123 cell suspension was removed 18 h after plating, which allowed selective attachment of stromal cells.  
124 The removed cell suspension was then re-seeded and incubated allowing epithelial cells to adhere.  
125 Stromal and epithelial cell populations were distinguished by cell morphology. Only epithelial  
126 endometrial cells were used in this study.

127 Amniotic and endometrial cells were cultured in a *medium* composed of HG-DMEM supplemented  
128 with 10% fetal calf serum (FCS), 1% penicillin (100 UI/mL)–streptomycin (100 mg/mL), 0.25  
129 mg/mL amphotericin B and 2 mM L-glutamine. Both cell lines were incubated at 38.5°C in a  
130 humidified atmosphere of 5% CO<sub>2</sub>, until they reached passage (P) 3. Endometrial cells reached P3  
131 in eight days while amniotic cells in ten days.

132

### 133 **Immunocytochemical detection of pancytocheratin**

134 Amniotic and endometrial epithelial cells were tested for immunoreactivity against pancytokeratin  
135 (mouse monoclonal, clone A1E; Santa Cruz Biotechnology, Santa Cruz, CA, USA) using primary  
136 antibody (anti PanCytokeratin: 1/200) diluted in TBST and secondary antibody conjugated with  
137 horseradish peroxidase (HRP) as described by Lange-Consiglio et al. (2015).

138

### 139 **Conditioned *medium*, microvesicles and supernatant production**

140 For CM production, cells at P3 at confluence were cultured for 5 days in a serum-free *medium*  
141 (Ultraculture, Lonza, Milan, Italy). Conditioned *media* of three samples from each cell line were  
142 collected, pooled, centrifuged at 3500 x g for 20 min to remove cellular debris. Control *medium*,  
143 (non-conditioned *medium*; no-CM), was generated in the same way as above, except that no cells  
144 were cultured in the plates.

145 A portion of CM *in toto* was stored at -80°C. To obtain MVs and SN, another portion of CM was  
146 ultra-centrifuged (Beckman Coulter Optima L - 100K) at 100,000 x g for 1h at 4°C. SN was  
147 collected and stored at - 80°C for later use. The pellet was washed in serum-free *medium* 199  
148 containing N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES) 25 mM and submitted to  
149 a second ultra-centrifugation under the same conditions. The resulting pellet, composed of MVs,  
150 was fractionated for MVs analysis or used for the *in vitro* test.

151

### 152 **Measurements of MVs**

153 Size and concentration of MVs were evaluated by NanoSight LM10 instrument (Nanoparticle  
154 tracking analysis, NTA, Nano-Sight Ltd., Amesbury, U.K.), which permits discrimination of  
155 microparticles less than 1 µm in diameter, as described by Bruno et al. (2009).

156

### 157 **MVs labeling with PKH-26**

158 To trace MVs *in vitro* by fluorescence microscopy, MVs from AMCs and ECs were labeled with the

159 red fluorescence aliphatic chromophore intercalating into lipid bilayers PKH-26 dye. Briefly, after  
160 ultra-centrifugation, the MV pellet was diluted to 1 mL with PKH-26 kit solution and 2  $\mu$ L of  
161 fluorochrome were added to this suspension and incubated for 30 min at 38.5°C. Thereafter, 7 mL  
162 of serum free DMEM were added to the suspension that was ultra-centrifuged again at 100,000 x g  
163 for 1 h at 4°C. The final pellet was immediately cryopreserved at -80°C.

164

### 165 ***In vitro* embryo production in different IVC media**

#### 166 *Collection of oocytes and in vitro maturation (IVM)*

167 Ovaries were collected from slaughtered Holstein-Friesian cows (*Bos taurus*) whose age,  
168 genealogy, and physiological status were unknown. Ovaries were transported in sterile saline  
169 solution (0.9% NaCl) supplemented with 150 mg/L kanamycin and maintained at 30°C. About 5940  
170 oocytes, in twenty replications, were used to produce embryos to submit to IVC with different  
171 culture systems. Oocytes were retrieved by aspiration of 3-5 mm diameter follicles with 18 G  
172 needles. Cumulus–oocyte complexes (COCs) were selected and washed three times in pre-  
173 incubated TCM 199-Hepes buffered supplemented with 10% FCS.

174 *In vitro* maturation was performed for 24 h in TCM 199 Earl's Salt *medium* supplemented with 10%  
175 FCS, 5  $\mu$ g/mL LH (Lutropin, Vetoquinol, France), 0.5  $\mu$ g/mL FSH (Folltropin, Vetoquinol), 0.2 mM  
176 sodium pyruvate, 5  $\mu$ g/mL gentamycin and 1 mg/mL estradiol 17 $\beta$ . Cultures were performed in 70  
177  $\mu$ L droplets (up to 20 oocytes/droplet) of the *medium* under mineral oil, at 38.5°C in 5% CO<sub>2</sub>.

178

#### 179 *In vitro* fertilization (IVF)

180 *In vitro* fertilization was performed in Tyrode's-albumin-lactate-pyruvate (TALP) *medium*  
181 containing 2 mM penicillamine, 1 mM hypotaurine, 250 mM epinephrine, 20  $\mu$ g/mL heparin, 114  
182 mM NaCl, 3.2 mM KCl, 0.4 mM NaH<sub>2</sub>PO<sub>4</sub>, 10 mM sodium lactate, 25 mM NaHCO<sub>3</sub>, 0.5 mM  
183 MgCl<sub>2</sub>-6H<sub>2</sub>O, 2.0 mM CaCl<sub>2</sub>-2H<sub>2</sub>O, 6 mg/mL bovine serum albumin (BSA,), 5  $\mu$ l /mL gentamicin,  
184 0.2 mM sodium pyruvate. Frozen-thawed semen of a single bull of proven fertility was prepared by

185 Percoll density gradient (Amersham Pharmacia Biotec) (45/90%). Semen was thawed at 37°C for  
186 30 s, placed on the top of the Percoll gradient and centrifuged for 30 min at 300 x g. The semen  
187 suspension was diluted in the appropriate volume of fertilization medium to obtain a final  
188 concentration of  $10^7$  spermatozoa per mL. An aliquot of 10  $\mu$ L of semen was co-incubated with  
189 matured oocytes for 18 h at 38.5°C in 5% CO<sub>2</sub>. Cultures were performed in 70  $\mu$ l droplets (up to 20  
190 oocytes/droplet) of the *medium* under mineral oil. At the end of gamete co-culture, cumulus cells  
191 were completely removed and cumulus-free presumptive zygotes were randomly transferred into  
192 different culture system and cultured up to day 7.

193

#### 194 *In vitro culture (IVC)*

195 The standard *medium* for IVC was synthetic oviductal fluid with aminoacids (SOFaa; Holm et al.  
196 1999) composed of 1.1 M NaCl, 72 mM KCl, 12 mM KH<sub>2</sub>PO<sub>4</sub>, 7.4 mM MgSO<sub>4</sub>, 50 mM DL-  
197 lactate, 250 mM NaHCO<sub>3</sub>, 260 mM phenol red, 100 mM sodium pyruvate, 178 mM CaCl<sub>2</sub>·2H<sub>2</sub>O,  
198 125 mM Hepes sodium salt, 30.8 mM glutamine, 500 mM glycine, 84.2 mM alanine, 100X MEM  
199 non-essential, 100X BME, 2.8 mM Myo-Inositol, 340 mM trisodium citrate, 2% FCS, 0.005 gr/mL  
200 BSA, 0.2mM sodium pyruvate, 5  $\mu$ L/mL gentamicin.

201 At the beginning of the culture in SOFaa, presumptive zygotes were randomly assigned to a control  
202 group (CTR, no supplementation), or to one of the experimental groups in which SOFaa was  
203 supplemented with one of the a-cellular extracts on day 1 or 3 or 5. Experimental groups were  
204 resumed in table 1

205 In every culture condition, IVC was performed for 7 days in 5% O<sub>2</sub>, 5% CO<sub>2</sub> and 90% N<sub>2</sub> in  
206 humidified atmosphere at 38.5°C. Cultures were performed in 70  $\mu$ l droplets (up to 20  
207 oocytes/droplet) of the *medium*. In the standard protocol, the *medium* is renewed on days 3 and 6  
208 during the culture period. In this study, to avoid stress to the embryos and to allow the action of  
209 secretome, the *medium* was renewed on days 3 and 5, and these time points were chosen to add  
210 different components of the secretome to SOF. In the same days, also the control group was

211 renewed with SOF only.

212

### 213 **Evaluation of MVs uptake by blastocysts**

214 To confirm MVs incorporation into blastocysts, a group of IVC embryos was cultured in SOF  
215 supplemented with AMCs- and EDCs-MVs previously stained with PKH-26. mL On day 7,  
216 blastocysts were stained with Hoechst 33343 (10 µg/mL) and MVs incorporation was evaluated by  
217 intensity of fluorescence under fluorescent microscopy BX71 (Olympus). Labeled MVs were  
218 excited at 550 nm while emission wavelength was set at 567 nm. Hoechst 33342 dye was excited at  
219 353-365 nm while the emission wavelength was set at 460 nm. The intensity of fluorescence was  
220 detected by semiquantitative analysis by the microscope BX71 equipped with a Scion Corporation  
221 1394 video camera interfaced with a computer provided with software for image acquisition and  
222 analysis (Image-Pro Plus 5.1-Media Cybernetics; Immagini & Computer), as described by Lange-  
223 Consiglio et al. (2016).

224 In addition, confocal microscopy analysis to assess internalization of MVs was performed using a  
225 Leica SP2 laser scanning confocal microscope (Leica Microsystems Srl, Italy) equipped with a PL  
226 Fluotar 20x AN 0.5 Dry objective.

227

### 228 **Blastocyst production rate and viability evaluation**

229 On day 7, for the evaluation of blastocyst formation rate, embryos from control and experimental  
230 groups were counted. A set of the blastocysts was used to test viability, which was assessed by  
231 Hoechst 33342 and propidium iodide staining. Blastocysts were retrieved from the IVC drops,  
232 washed with PBS supplemented with 2% BSA and incubated with Hoechst 33342 (10 µg/mL) and  
233 propidium iodide (1 µg/mL) for 15 min at 38.5°C. Then, they were observed under fluorescent  
234 Olympus BX51 microscope at a magnification of 40x, analyzing the images with Image-Pro Plus  
235 5.1-Media Cybernetics software. Hoechst 33342 dye was excited at 353-365 nm while the emission  
236 wavelength was set at 460 nm. Propidium iodide was excited at 535 nm while the emission

237 wavelength was set at 617 nm.

238

### 239 **Differential staining**

240 Another set of control and experimental group embryos was used for differential staining.  
241 Differential staining was performed with propidium iodide and Hoechst 33342 after disrupting the  
242 membrane integrity of the surface trophectoderm cells by means of a detergent (Triton X-100),  
243 which permits penetration of the propidium iodide into the trophectoderm cells, but not into the  
244 inner mass cells (ICM). Since all the cells were stained with Hoechst 33342, in this way the ICM  
245 stained blue and the trophectoderm purple. The staining was performed according to Thouas et al.  
246 (2001) with some modifications. Briefly, prior to differential staining, embryos were washed in PBS  
247 supplemented with 5% FCS, then were permeabilized for 30 seconds in PBS containing 0.04%  
248 Triton X-100 and 0.1 mg/mL of propidium iodide. After that, embryos were stained with 10 µg/mL  
249 of Hoechst for 15 min at 38.5°C and mounted on a glass slide in a small drop of PBS. Four small  
250 pillars of wax were applied and a cover glass was laid over the drop applying a suitable pressure to  
251 visualize the cells for counting. Cell counting was performed from digital photographs obtained by  
252 a fluorescent Olympus BX51 microscope at a magnification of 40x at the wavelength previously  
253 described. The images were analysed, using Image Pro-Plus software, by a single operator in a  
254 blinded manner.

255

### 256 **Gene expression assessment in IVP bovine embryos on day 5 of treatment**

257 Genes involved in apoptosis (*BAX*; Bcl-2-associated X protein) and reactive oxygen species (ROS)  
258 protection (*GPX1*; glutathione peroxidase 1) were analyzed by reverse transcription-quantitative  
259 PCR (RT-qPCR) in embryos from both cell lines treated on day 5 with CM, MVs, and SN. The  
260 mRNA expression levels of all the cited genes were measured in three samples (biological  
261 replicates). Fifteen blastocyst for each group were collected on day 7 of culture, washed in sterile  
262 PBS and immediately placed in sterile RNase DNase-free Eppendorf tubes. Samples were kept at

263 -80°C until RNA extraction. RNA extraction was performed using Trizol followed by DNase  
264 treatment. The concentration of RNAs was evaluated three times using a NanoDrop ND-1000  
265 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). RNAs quality was checked  
266 using the Agilent Bioanalyser 2100 (Agilent, Santa Clara, CA). RT-qPCRs were performed with the  
267 High Capacity cDNA Reverse Trascripton Kit (Applied Biosystems/Life Technologies, Carlsbad,  
268 CA, USA) using 100 ng of RNA per reaction. All the qPCR experiments were run in triplicates  
269 (technical replicates) using the qPCR protocol described by TaqMan Fast Gene Expression Assays  
270 (Life Tecnologies™) on 7500 Fast Real-time PCR System instrument (Applied Biosystems by Life  
271 Technologies™). To assess gene expression, each target gene and the *GAPDH*, as the housekeeping  
272 control gene, were co-amplified. Conditions of amplifications were an initial step of 95°C (3  
273 minutes), followed by 40 cycles of 95°C (30 seconds), 60°C (30 seconds), and 72°C (20 seconds),  
274 followed by the acquisition of the melting curve (fluorescence acquisition every 0.5°C). Efficiency  
275 of amplification for each primer was monitored through the analysis of serial dilution. Additional  
276 dissociation curve analysis was performed and in all cases showed a single peak.

277 Average target gene threshold cycle ( $\Delta Ct_g$ ) for each sample (calculated using the CT values of the  
278 technical replicates within each experimental conditions), were normalized to the average *GAPDH*  
279 values ( $\Delta Ct_{GAPDH}$ ) of the same cDNA sample. Then, the expression variations calculated were  
280 normalized to internal control (i.e. CTR) using the  $\Delta\Delta Ct$  method. Finally, the fold change  
281 expression of each gene was calculated as  $2^{-\Delta\Delta Ct}$  (Livak and Schmittgen, 2001). Primers from each  
282 gene were designed using Primer3 web interface ([www.primer3plus.com](http://www.primer3plus.com)). The assay primers were  
283 available and synthesized by Life technologies™.

284 **BAX:** Forward AGAGGATGATCGCAGCTGTGGA;

285 Reverse CAAAGATGGTCACTGTCTGCCATGT; (bp = 300); Gene Bank access NM\_173894.1

286 **GPXI:** Forward GCAACCAGTTTGGGCATCA; Reverse CTCGCACTTTTCGAAGAGCATA; (bp  
287 = 116); Gene Bank access NM\_174076.3.

288 **GAPDH:** Forward TTCAACGGCACAGTCAAGG; Reverse ACATACTCAGCACCAGCATCA;

289 (bp = 119); Gene Bank access NM\_001034034.2

290

## 291 **Statistical analysis**

292 Statistical analysis was performed using full factorial model, with polynomial contrasts for within-  
293 subjects factor and between-subjects factor.

294 For RT-qPCR expression, Kruskal–Wallis and Mann–Whitney nonparametric tests were performed  
295 to analyze relative mRNA abundance. Differences were considered statistically significant at the  
296 95% confidence level and  $P < 0.05$ . Data were analyzed with GraphPad InStat 3.00 for Windows  
297 (GraphPad software, Inc. La Jolla, CA, USA).

298

## 299 **RESULTS**

### 300 **Cell isolation**

301 The initial viability of EDCs and AMCs was  $>90\%$ . EDCs and AMCs showed ability to adhere to  
302 flask and typical polygonal epithelial morphology (Fig 1 A,B). Immunopositivity to  
303 pancytocheratin confirmed that both cells lines were of epithelial origin (C,D). Previous molecular  
304 biological analyses on AMCs at P3 showed that these cells displayed a typical stem cell phenotype,  
305 with the expression of markers, such as CD29, CD44, CD106, CD105, and MHCI, but not CD34  
306 and MHCII, as reported by Corradetti et al. (2013).

307 Previous molecular biology studies on EDCs have confirmed their endometrial nature due to the  
308 expression of *ER-A*, *ER-B*, *PR* and *TP53* (Marini et al. 2016).

309

### 310 **MVs identification and uptake in bovine blastocyst**

311 The 100,000 g fractions isolated in this study and measured using NanoSight Instruments showed a  
312 major peak in each preparation between 226-363 nm for EDCs (Fig 2A) and 220-295 nm for AMCs  
313 (Fig 2B). NanoSight analysis determined that amniotic MVs had a dimension between 50 nm and  
314 670 nm, with a mean of  $258 \pm 55$  nm. Considering the seeding density and the amount of MVs

315 obtained it possible to speculate that AMCs produced about 800 to 4700 MVs/cell, with a mean of  
316  $2550 \pm 71$  MVs/cell, corresponding to  $540 \times 10^6$  MVs/mL of CM. Endometrial cells instead produced  
317 MVs with a dimension between 199 nm and 337 nm with a mean of  $238 \pm 40$  nm. Endometrial cells  
318 produced about 2762 to 3414 MVs/cell with a mean of  $3166 \pm 329$  MVs/cell, corresponding to  
319  $670 \times 10^6$  MVs/mL of CM.

320 Fluorescent microscope analysis demonstrated that both amniotic and endometrial MVs were  
321 internalized into blastomeres. Blastomere nuclei were stained in blue by Hoechst 33342 (Fig 3A)  
322 and MVs in red by PKH-26 (Fig 3B). MVs incorporation was better evaluated by the merging of  
323 blue and red images (Fig 3C). Previously, a dose–response curve was studied with different  
324 concentration of MVs (10-20-40-60-80-100-150  $\times 10^6$  MVs/mL) revealing that the concentration of  
325  $100 \times 10^6$  MVs/mL provided the more intense fluorescence signal (data not shown). We calculated  
326 that  $100 \times 10^6$  MVs are present in about 20% of CM of both cell lines and, for this reason, SOF was  
327 supplemented with 20% of CM or SN.

328 As seen by confocal microscopy, after incubation with labeled MVs, blastomeres showed a fine  
329 granular fluorescent pattern within their cytoplasm at the same nuclei plane, indicating  
330 incorporation of MVs (Fig 3D).

331

### 332 **Blastocyst rate**

333 A total of 5840 oocytes were fertilized over the course of this experiment that consisted of twenty  
334 replicates. The number of embryos obtained in all the different experimental conditions was 1453.

335 Embryo morphology was evaluated on day 7 after fertilization under a stereomicroscope (Leica)  
336 and the embryos were grouped according to stage (morula, compact morula and blastocyst). Poor  
337 quality morulas/compact morulas were classified as degenerate if there was loss of plasma  
338 membrane integrity (lysis) and/or generalized loss of cell forms.

339 Blastocyst formation rates obtained from the different fractions of secretome are showed in Fig 4. In  
340 CTR, blastocyst formation rate was  $35.45 \pm 2.53\%$ .

341 No blastocysts were produced in either CM and SN by either cell line on day 1. Amniotic and  
342 endometrial MVs on day 1 produced  $24.24\pm 2.75\%$  and  $26.19\pm 2.82\%$  of blastocysts, respectively.  
343 These results were not statistically different ( $P>0.05$ ) from each other but different ( $P<0.05$ )  
344 compared to the CTR.

345 On day 3, CM and MVs, but not SN, of both cell lines provided embryos. Only amniotic MVs gave  
346 a rate of embryos comparable to CTR, while the other experimental conditions provided numbers  
347 that were statistically lower ( $P<0.05$ ) when compared to CTR.

348 On day 5, amniotic CM and MVs provided blastocyst formation of  $34.17\pm 3.29\%$  and  $34.85\pm 3.66\%$   
349 respectively, and there was no statistical difference ( $P<0.05$ ) between these results and CTR. The  
350  $25.80\pm 2.83\%$  rate produced by amniotic SN on day 5 was statistically lower ( $P<0.05$ ) than all the  
351 other groups previously described. All the blastocyst rates obtained by endometrial CM, SN or MVs  
352 used on day 5 were statistically lower than amniotic secretome and CTR ( $21.69\pm 1.87$ ,  $13.70\pm 2.05$   
353 and  $29.27\pm 2.44\%$ , respectively).

354

### 355 **Embryo viability evaluation**

356 The number of embryos used for viability evaluation in all experimental conditions, was 652. The  
357 viability results of embryos obtained on exposure to different fractions of secretome are shown in  
358 Fig 5. Figure 6 A shows an embryo on day 7. Figures 6 B,C and 6 D,E show embryos treated  
359 respectively by amniotic derived MVs and endometrial derived MVs on day 5. Their corresponding  
360 stainings were performed on day 7. In embryo treated by endometrial MVs, a reduced inner cell  
361 mass and a greater number of non viable blastomers were observed.

362 The rate of blastomeres viability in CTR was  $92.36\pm 4.48\%$ .

363 Almost all experimental conditions that produced embryos provided a viability rate that was not  
364 statistically different ( $P<0.05$ ) compared to the CTR. Three conditions, namely endometrial CM  
365 added on day 3, ( $83.61\pm 5.18$ ), endometrial SN added on day 5 ( $84.29\pm 2.71$ ) and endometrial MVs  
366 added on day 5 ( $85.98\pm 2.77$ ) provided statistically significant lower viability compared to CTR.

367 The only treatments that statistically ( $P<0.05$ ) enhanced viable blastomere production more than the  
368 CTR were amniotic CM and MVs added on day 5 ( $99.4\pm 4.83$  and  $98.56\pm 3.27\%$  respectively).

369

### 370 **Embryo quality evaluation**

371 The number of embryos of all experimental conditions used for differential staining was 666.

372 Quality of embryo obtained by different fractions of secretome is showed in Table 2, 3, 4. Figure. 6

373 C shows the differential staining in an embryo on day 7, while Fig 7 displays the number of ICM.

374 The rate of ICM/trophoblast in CTR was  $29.65\pm 2.03$ .

375 When blastocysts were differentially stained to permit the counting of the inner cell mass and

376 trophectoderm, the rate of ICM/trophoblast was statistically similar ( $P>0.05$ ) to CTR for all the

377 experimental condition with two exceptions. Namely, amniotic and endometrial MVs, added on day

378 1, gave a lower rate ( $P<0.05$ ) of ICM/trophoblast than the CTR, while amniotic CM and MVs added

379 on day 5, provided a quality of embryos that was statistically better ( $P<0.05$ ) than the control and

380 the other groups. This increase is due to the statistically higher number ( $P<0.05$ ) of ICM cells in the

381 amniotic CM and MVs treated embryos compared to the CTR ( $33.66\pm 1.93$  and  $34.42\pm 1.27$  vs

382  $27.6\pm 1.44$ , respectively). On the contrary, the number of trophoblast cells in these experimental

383 conditions was similar.

384

### 385 **Embryo gene expression**

386 With regard to genes related to apoptosis, *BAX* was significantly ( $P<0.05$ ) downregulated in groups

387 treated with CM and MVs secreted by AMCs ( $0.5\pm 0.12$  and  $0.5\pm 0.13$ , respectively) but up-

388 regulated with SN of both cell lines compared to CTR group ( $P<0.05$ , Fig 8 A). *GPXI* (Fig 8 B),

389 was significantly upregulated ( $P<0.05$ ) for treatments with CM and MVs secreted by AMCs

390 compared to CTR group ( $3.2\pm 0.27$  and  $4.0\pm 0.37$ ). *GPXI* expression in AMC-MVs was statistically

391 different ( $P<0.05$ ) compared to AMC-CM.

392

## 393 **DISCUSSION**

394 As is well know, IVP embryos have a lower quality, a lower number of blastomeres and a higher  
395 apoptosis rate compared to those produced *in vivo* in different animal species (Booth et al. 2005;  
396 Gjorret et al. 2005; Pomar et al. 2005). In addition, it is known that their implantation rate after  
397 transfer is low (Kikuchi et al. 2002; Berg et al. 2010; Bakri et al. 2016).

398 To improve embryo quality, usually, *in vitro* blastocyst production is performed with feeder cells,  
399 mainly oviduct and uterine epithelial cells, to mimic *in vivo* conditions. This suggests that paracrine  
400 or autocrine communication between helper cells and embryos is present. During *in vitro* culture,  
401 helper cells secrete many growth factors, receptors and binding proteins into the culture *medium*  
402 (Van Langendonck et al. 1996; Zquierdo et al. 1999). The potential of this *medium*, called CM, was  
403 already established by Ijaz et al. (1994) and Zhu et al. (1994) that defined the CM as a complex  
404 matrix of growth factors, cytokines and glycoproteins, secreted from cells, that may influence the  
405 development of early embryos pre-implantation. In some experiments, the use of CM provided  
406 embryo developmental rates similar to those obtained in the co-culture systems (Kobayashi et al.  
407 1992; Mermillod et al. 1993; Lee et al. 2003), with the benefit of not having animal cells in the  
408 embryo culture. To date, the individual effects of the components of CM on *in vitro* embryo  
409 development has not been investigated. Lopera-Vásquez et al. (2016) evaluated the effect of CM  
410 and extracellular vesicles (EVs) derived from bovine oviduct epithelial suggesting that EVs provide  
411 functional communication between the oviduct and the embryo in the early stage of development.  
412 These authors did not study the effect of soluble factors (SN) only and the incorporation of MVs  
413 inside the blastomeres. Since the embryo interacts both with the uterus, for implantation, and with  
414 the placenta, this study investigated the effect of different components of endometrial and amniotic  
415 cell secretome on the IVP embryos development.

416 In this study, we first identified the presence of MVs in CM produced by both amniotic and  
417 endometrial cell culture. By their size, these MVs could be classified as shedding vesicles, also  
418 known as ectosomes or microparticles, that originate from direct budding and ‘blebbing’ of the

419 plasma membrane. These shedding vesicles are different from exosomes that arise from the cell  
420 membrane endosomal compartment and are released into the extracellular space after fusion of  
421 multivesicular bodies with the plasma membrane. Exosomes tend to be homogeneous in size (30-  
422 120 nm) while shedding vesicles are more heterogeneous (ranging from 100 nm to 1  $\mu$ m). MVs  
423 found in amniotic and endometrial CM are similar in size ( $258\pm 55$  nm for AMCs and  $238\pm 40$  nm  
424 for EDCs) even if, in the same culture conditions and density of seeding, the EDCs produced more  
425 MVs than AMCs ( $670\times 10^6$  MVs/mL vs  $540\times 10^6$  MVs/mL). Obviously, these data refer to an *in*  
426 *vitro* study and no information about their production in *in vivo* conditions are available.

427 In this study, the control *medium* (no-CM) was tested to verify whether components of the original  
428 *medium* used for culture had any effect on *in vitro* embryo production. No blastocysts were obtained  
429 and development was arrested at early morula stage (data not shown). This is probably due to the  
430 high level of glucose contained in HG-DMEM. Indeed, some results on post-fertilization embryo  
431 development confirm that glucose has a detrimental effect on the course of *in vitro* embryo culture  
432 (Kim et al. 1993; Gutiérrez-Adán et al. 2001). Conversely, during cell metabolism, the level of  
433 glucose in CM decreases because it is converted to lactate and pyruvate (Pereira et al. 2014).

434 Next, the CM *in toto* and its different components, MVs and SN, were used on different days during  
435 embryo culture to study the temporal effect, considering the changing nutritional requirements of  
436 the embryo during its development.

437 The results of our study suggest that the exposure of bovine embryos at different times of culture to  
438 the various fractions of secretome of both cell lines provides dissimilar rates of blastocyst  
439 formation. Among the different experimental conditions, the best results were obtained when  
440 supplementation started on day 5, corresponding also, in the case of amniotic CM and MVs, to the  
441 better culture conditions for embryo quality. Indeed, this condition did not improve the blastocyst  
442 rate compared to the CTR but enhanced the quality of embryos as observed by the increase of  
443 ICM/trophoblast rate and by the proportion of viable blastomeres produced. In all the other  
444 conditions, the rate of blastocyst production was lower than CTR and, in the main, the results

445 obtained by endometrial CM, SN or MVs used on day 5 were lower than those obtained by  
446 amniotic secretome and CTR groups. In almost all the experimental conditions that reduced the  
447 total number of cells, or that of the inner mass cells, a decrease in embryo viability was noted.  
448 Moreover, the data obtained by addition of amniotic CM *in toto* or MVs were equivalent while  
449 blastocysts number and quality provided by SN were always scarce or insignificant.  
450 These data were confirmed by gene expression evaluation performed only on day five of treatment.  
451 This time point was chosen because on day 5 embryos were produced in all the fractions of  
452 secretome from both cell lines and, qualitatively, only amniotic CM and MVs produced statistically  
453 greater inner cell mass than CTR. There is still not full agreement between studies on the set of  
454 genes that will reflect accurately the effect of different culture conditions on embryo quality  
455 (Cordova et al. 2014). Therefore, we selected two genes related to apoptosis and protection against  
456 ROS, respectively. Melka et al. (2010) reported that *Bax* pro-apoptotic gene expression could be a  
457 potential quality marker as they found an upregulation of this gene in poor quality 4-cell  
458 preimplantation embryos with a higher DNA fragmentation, compared with morphologically good  
459 quality embryos at the same stage. Our study, indeed, found a downregulation of this gene in groups  
460 treated by CM and MVs secreted by AMCs compared to CTR group ( $P < 0.05$ ) and up-regulation in  
461 groups treated by SN of both cell lines.  
462 The embryo relies on the activity of certain antioxidant enzymes to protect itself from oxidative  
463 stress (Harvey et al. 1995), so we evaluated mRNA expression of *GPXI* gene to investigate the  
464 effect of different components of the secretome on embryo defense mechanisms against ROS.  
465 GPX1 deficiencies can make cells more susceptible to possible stressors leading to an increase in  
466 apoptosis. In support of this, the CTR group in our study shows less abundant *GPXI* mRNA  
467 compared to groups exposed to CM and MVs secreted by AMCs, suggesting its susceptibility to  
468 ROS damage. Moreover, the expression of *GPXI* in amniotic MVs is higher than in amniotic CM.  
469 Probably, the MVs exert an anti-apoptotic effect on embryo, down-regulating the *Bax* gene and up-  
470 regulating the *GPXI* gene, in the same way of MVs derived by stem cells, as demonstrated *in vitro*

471 by Bruno et al. (2012). These authors demonstrated that bone-marrow derived MVs up-regulated  
472 anti-apoptotic genes, such as B-cell lymphoma-extra large (*Bcl-xL*), B-cell lymphoma 2 (*Bcl2*) and  
473 baculoviral IAP repeat containing 8 (*BIRC8*), and down-regulated genes that have a central role in  
474 the execution-phase of cell apoptosis such as caspase-1 (*Casp1*), caspase-8 (*Casp8*) and  
475 limphotoxin alpha (*LTA*), in cisplatin-treated human tubular epithelial cells. This effect is, perhaps,  
476 attributable to the transfer of microRNA from MVs to target cells (in our case, the embryos).

477 The reasons for the good results on day 5 of supplementation are not clear, and can only be  
478 hypothesized. In bovine species, activation of the genome starts between the 8 and 16 cell stage,  
479 corresponding, to the embryonic stage attained *in vitro*, between days 2 and 4 of culture. The  
480 embryo at this stage may be more susceptible to the influence of culture conditions compared to  
481 other developmental stages (Xu et al. 2001). Environmental changes at this stage could disturb the  
482 activation of the embryonic genome and this would explain why amniotic and endometrial  
483 secretomes do not favor embryonic development. In fact, the supplementations on the 5<sup>th</sup> day  
484 increased the development of blastocysts. Moreover, these findings mirror those in mouse studies  
485 where two periods (between 48 and 72 hours, and between 72 and 120 hours), during which  
486 embryos are more responsive to culture conditions, are recognized (Xu et al. 2001). Furthermore,  
487 day 5 mimics the time at which the bovine embryo enters the uterus following fertilization. It is  
488 important to underline that amniotic secretome appears more suitable than the endometrial one. This  
489 result was surprising but it is likely that endometrial epithelial cells de-differentiate during culture  
490 in monolayers. Some authors (Rottmayer et al. 2006; Sostaric et al. 2008; Gualtieri et al. 2009;  
491 Ulbrich et al. 2010) reported that these cells lose cell polarity, cell height, ciliation, secretory  
492 activity, and responsiveness to hormones, showing signs of alteration after 24-48 h post confluence.  
493 In this way, the secretions produced by these cells *in vitro* are different compared to the *in vivo*  
494 secretions. Moreover, it is probably that amniotic and endometrial secretomes contain different  
495 components and that these differences cause different degrees of development. It is also probable  
496 that a different secretome of amniotic and endometrial cells is attributable to the different age of

497 these tissue (adult for endometrium and fetal for amnion) but no data in literature support this  
498 hypothesis. At this stage, we have not investigated the composition of secretome but it is known  
499 that CM contain many factors secreted by somatic cells. Indeed, some studies have shown that  
500 many factors, such as EGF, PDGF, LIF, IL6, IL1, bFGF, VEGF (Kobayashi et al. 1992; Baranao et  
501 al. 1997; Ishiwata et al. 2000), and embryotrophic factors (Xu et al. 2001) are secreted from the  
502 cells in co-culture and, therefore, are also present in the CM. It is the authors' belief, as supported  
503 by the present study, that soluble factors do not affect the quality of embryos produced because  
504 embryos developed in SN (that only contains soluble factors) did not show the benefits. As a matter  
505 of fact, MVs produced the best results when added, either alone, or as components of CM *in toto*,  
506 while positive benefits were not seen when soluble factors in CM deprived of MVs were provided.  
507 Moreover, we demonstrated that embryos can uptake labeled MVs and it is possible there is a  
508 mechanism of transfer of the MVs contents within the blastomeres.

509 To our knowledge no published literature relating to the incorporation of MVs of any origin into the  
510 blastocyst exists. An unanswered question is which of the molecules contained in MVs are involved  
511 in this communication. Recently, several studies have focused on miRNAs. These small, non-  
512 coding, RNA molecules are present in many biological fluids such as follicular fluid and culture  
513 *media* (Rosenbluth et al. 2014). While total miRNAs in human bio-fluids or supernatants from cell  
514 cultures may be released from apoptotic cells or cell debris, MVs miRNAs are actively released by  
515 viable cells and are thought to represent an active means of communication between cells and  
516 tissues both locally or systemically. In particular, MV-encapsulated miRNAs are shielded from  
517 degradation and are remarkably stable in biological fluids. Specifically, miRNAs that are  
518 encapsulated in MVs might have a different role compared with miRNAs in bio-fluids as they can  
519 transfer biological information to recipient cells (Machtinger et al. 2016).

520 Certainly, the presence of amniotic MVs improved embryo quality, compared to endometrial MVs,  
521 by transfer of specific amniotic progenitor cell signals or material. We did not investigate the  
522 different expression profile of miRNAs between amniotic and endometrial MVs. In our study, we

523 can only see their functional influence on embryo development. MiRNAs play an essential  
524 regulatory role during development, indeed, aberration of blastocyst miRNA expression is  
525 associated with human infertility (McCallie et al. 2010). It could be that miRNAs, transferred by  
526 MVs within the blastocyst, contribute to the miRNA content of the blastocyst itself promoting their  
527 development and quality. Moreover, it is likely that amniotic secretome promotes embryo  
528 development in a more physiological way than endometrial secretomes, but further experiments are  
529 planned to better explain these data and to better understand the cargo of MVs in both cell lines.

530 In conclusion, it is known that co-culture systems improve the *in vitro* development of embryos, but  
531 our results suggest that MVs (along with their miRNA contents) are probably involved in this effect.  
532 Indeed, the present study demonstrated that the brief *in vitro* exposure of embryos to amniotic CM  
533 and MVs, but not to soluble factors (SN), improved embryo quality. It is essential to achieve a good  
534 blastocyst formation rate in IVP and, in this study, culture with amniotic MVs gave a similar  
535 formation rate to CTR. On the other hand, it is mandatory that IVP embryos should be of the  
536 highest possible quality at the blastocyst stage to ensure optimal pregnancy rates after transfer,  
537 especially after freezing and thawing. Amniotic MVs induced an increase of ICM and changes in  
538 the profile of expression of some genes known to be related to embryo quality, suggesting reduced  
539 apoptosis and increased capacity to survive oxidative stress. If relevant miRNAs and functional  
540 targets can be identified, a possible clinical use for these molecules will represent the next front line  
541 and may lead to novel strategies for better enhancing or manipulating reproductive efficiency.  
542 Moreover, this study may provide a useful starting point for further studies related to paracrine  
543 mechanisms of communications between embryos and culture *medium*.

544

#### 545 **ACKNOWLEDGEMENTS**

546 The authors wish to thank Dott.ssa Maria Chiara Deregibus and Prof. Giovanni Camussi  
547 (Department of Internal Medicine and Molecular Biotechnology Center, University of Torino,  
548 Torino, Italy) for their skilled assistance in Nanosight instrument use, and Dott.ssa Miriam Ascagni

549 (Department of Biology, Università degli Studi di Milano, Milano, Italy) for her skilled assistance  
550 in confocal microscopy.

551 Authors wish to thank Vetoquinol for providing the Lutropin used in the IVM protocol.

552

### 553 **CONFLICT OF INTEREST**

554 The authors declare that no conflict of interest and no competing financial interests exist in relation  
555 to this manuscript.

556

### 557 **REFERENCES**

558 Bakri, N.M., Ibrahim, S.F., Osman, N.A., Hasan, N., Jaffar, F.H.F., Rahman, Z.A., Osman, K.  
559 (2016). Embryo apoptosis identification: Oocyte grade or cleavage stage? *Saudi J Biol Sci* **23**, S50-  
560 S55.

561 Baranao, R.I., Piazza, A., Rumi, L.S., Polak de Fried, E. (1997) Determination of IL-1 and IL-6  
562 levels in human embryo culture-conditioned media. *Am J Reprod Immunol* **37**, 191-194.

563 Berg, D.K., van Leeuwen, J., Beaumont, S., Berg, M., Pfeffer, P.L. (2010). Embryo loss in cattle  
564 between Days 7 and 16 of pregnancy. *Theriogenology* **15**, 250-260.

565 Booth, P.J., Holm, P., Callesen, H. (2005). The effect of oxygen tension on porcine embryonic  
566 development is dependent on embryo type. *Theriogenology* **63**, 2040-2052.

567 Grange, C., Deregibus, M.C., Calogero, R.A, Saviozzi, S., Collino, F., Morando, L., Busca, A.,  
568 Falda, M., Bussolati, B., Tetta, C., Camussi, G. (2009). Mesenchymal stem cell-derived  
569 microvesicles protect against acute tubular injury. *J Am Soc Nephrol* **20**, 1053-1067.

570 Bruno, S., Grange, C., Collino, F., Deregibus, M.C., Cantaluppi, V., Biancone, L., Tetta, C.,  
571 Camussi, G. (2012). Microvesicles derived from mesenchymal stem cells enhance survival in a  
572 lethal model of acute kidney injury. *PLoS One* **7**, e33115.

573 Bruno, S., Grange, C., Deregibus, M.C., Calogero, R.A., Saviozzi, S., Collino, F., Morando, L.,  
574 Busca, A., Falda M., Bussolati, B, Tetta, C., Camussi, G. (2009). Mesenchymal stem cell-derived  
575 microvesicles protect against acute tubular injury. *J Am Soc Nephrol* **20**, 1053-1067.

- 576 Burns, G., Brooks, K., Wildung, M., Navakanitworakul, R., Christenson, L.K., Spencer, T.E. (2014).  
577 Extracellular vesicles in luminal fluid of the ovine uterus. *PLoS One* **9**, e90913.
- 578 Camussi, G., Deregibus, M.C., Bruno, S., Cantaluppi, V., Biancone, L. (2010).  
579 Exosomes/microvesicles as a mechanism of cell-to-cell communication. *Kidney Int* **78**(9), 838-848.
- 580 Cordova, A., Perreau, C., Uzbekova, S., Ponsart, C., Locatelli, Y., Mermillod, P. (2014).  
581 Development rate and gene expression of IVP bovine embryos cocultured with bovine oviduct  
582 epithelial cells at early or late stage of preimplantation development. *Theriogenology* **81**, 1163-  
583 1173.
- 584 Corradetti, B., Meucci, A., Bizzaro, D., Cremonesi, F., Lange Consiglio, A. (2013). Mesenchymal  
585 stem cells from amnion and amniotic fluid in bovine. *Reproduction* **14**, 391-400.
- 586 Donofrio, G., Franceschi, V., Capocéfalo, A., Cvirani, S., Sheldon, I.M. (2008). Bovine  
587 endometrial stromal cells display osteogenic properties. *Reprod Biol Endocrinol* **6**, 65-73.
- 588 Gjorret, J.O., Wengle, J., Maddox-Hyttel, P., King, W.A. (2005). Chronological appearance of  
589 apoptosis in bovine embryos reconstructed by somatic cell nuclear transfer from quiescent  
590 granulosa cells. *Reprod Domest Anim* **40**, 210-216.
- 591 Gualtieri, R., Mollo, V., Braun, S., Barbato, V., Fiorentino, I., Talevi, R. (2012). Long-term viability  
592 and differentiation of bovine oviductal monolayers: bidimensional versus three-dimensional culture.  
593 *Theriogenology* **78**, 1456-1464.
- 594 Gutiérrez-Adán, A., Granados, J., Pintado, B., de la Fuente, J. (2001). Influence of glucose on the  
595 sex ratio of bovine IVM/IVF embryos cultured in vitro. *Reprod Fertil Dev* **13**, 361-365.
- 596 Harvey, M.B., Arcellana-Panlilio, M.Y., Zhang, X., Schultz, G.A., Watson A.J. (1995). Expression  
597 of genes encoding antioxidant enzymes in preimplantation mouse and cow embryos and primary  
598 bovine oviduct cultures employed for embryo coculture. *Biol Reprod* **53**, 532-540.
- 599 Holm, P., Booth, P.J., Schmidt, M.H., Greve, T., Callesen, H. (1999) High bovine blastocyst  
600 development in a static in vitro production system using sofaa medium supplemented with sodium  
601 citrate and myo-inositol with or without serum-proteins. *Theriogenology* **52**, 683-700.
- 602 Ijaz, A., Lambert R.D., Sirard, M.A. (1994). In vitro cultured bovine granulosa and oviductal cells  
603 secrete sperm motility maintaining factor(s). *Mol Reprod Dev* **37**(1), 54-60.

- 604 Ishiwata, I., Tokieda, Y., Kiguchi, K., Sato, K., Ishikawa, H. (2000). Effects of embryotrophic  
605 factors on the embryogenesis and organogenesis of mouse embryos in vitro. *Hum Cell* **13**, 185-195.
- 606 Izquierdo, D., Villamediana, P., Paramio, M.T. (1999). Effect of culture media on embryo  
607 development from prepubertal goat IVM-IVF oocytes. *Theriogenology* **52**, 847-861.
- 608 Kikuchi, K., Onishi, A., Kashiwazaki, N., Iwamoto, M., Noguchi, J., Kaneko, H., Akita, T., Nagai,  
609 T. (2002). Successful piglet production after transfer of blastocysts produced by a modified in vitro  
610 system. *Biol Reprod* **66**, 1033-1041.
- 611 Kim, J.H., Niwa, K., Lim, J.M, Okuda, K. (1993). Effects of phosphate, energy substrates, and  
612 amino acids on development of in vitromatured, in vitro-fertilized bovine oocytes in a chemically  
613 defined, protein-free culture medium. *Biol Reprod* **48**, 132-135.
- 614 Kobayashi, K., Takagi, Y., Satoh, T., Hoshi, H., Oikawa, T. (1992). Development of early bovine  
615 embryos to the blastocyst stage in serum-free conditioned medium from bovine granulosa cells. *In*  
616 *Vitro Cell Dev Biol* **28**, 255-259.
- 617 Lange-Consiglio, A., Accogli, G., Cremonesi F., Desantis S. (2015) Cell surface glycan changes in  
618 the spontaneous epithelial–mesenchymal transition of equine amniotic multipotent progenitor cells.  
619 *Cells Tissues and Organs* **200**, 212-226.
- 620 Lange-Consiglio, A., Maggio, V., Pellegrino, L., Cremonesi, F. (2010). Equine bone marrow  
621 mesenchymal or amniotic epithelial stem cells as feeder in a model for the in vitro culture of bovine  
622 embryos. *Zygote* **20**, 45-51.
- 623 Lange-Consiglio, A., Perrini, C., Tasquier, R., Deregibus, M.C., Camussi, G., Pascucci, L., Marini,  
624 M.G., Corradetti, B., Bizzaro, D., De Vita, B., Romele, P., Parolini, O., Cremonesi, F. (2016)  
625 Microvesicles secreted from equine amniotic-derived cells and their potential role in reducing  
626 inflammation in a tendon in vitro model. *Stem Cell Develop* **25**, 610-621.
- 627
- 628 Lee, Y.L., Lee, K.F., Xu, J.S., Kwok, K.L., Luk, J.M., Lee, W.M., Yeung W.S. (2003).  
629 Embryotrophic factor-3 from human oviductal cells affects the messenger RNA expression of  
630 mouse blastocyst. *Biol Reprod* **68**, 375-382.
- 631 Li, X., Morris, L.H.A., Allen, W.R. (2001). Influence of coculture during maturation on the  
632 developmental potential of equine oocytes fertilized by intracytoplasmic sperm injection (ICSI).  
633 *Reproduction* **121**, 925-932.

- 634 Livak, K.J., Schmittgen, T.D. (2001). Analysis of relative gene expression data using realtime  
635 quantitative PCR and the 2- $\Delta\Delta$ CT method. *Methods* **25**, 402-408.
- 636 Lonergan, P., Carolan, C., Van Langendonck, A., Donnay, I., Khatir, H., Mermillod, P. (1996). Role  
637 of epidermal growth factor in bovine oocyte maturation and preimplantation embryo development  
638 in vitro. *Biol Reprod* **54**, 1420-1429.
- 639 Lopera-Vásquez, R., Hamdi, M., Fernandez-Fuertes, B., Maillo, V., Beltrán-Breña, P., Calle, A.,  
640 Redruello, A., López-Martín, S., Gutierrez-Adán, A., Yañez-Mó, M., Ramirez MÁ, Rizo, D.  
641 (2016). Extracellular vesicles from BOEC in in vitro embryo development and quality. *PLoS One*  
642 **11**(2), e0148083.
- 643 Machtiger, R., Laurent, L.C., Baccarelli, A.A. (2016). Extracellular vesicles: roles in gamete  
644 maturation, fertilization and embryo implantation. *Hum Reprod Update* **22**, 182-193.
- 645 Marini, M.G., Perrini, C., Esposti, P., Corradetti, B., Bizzaro, D., Riccaboni, P., Fantinato, E.,  
646 Urbani, G., Gelati, G., Cremonesi, F., Lange-Consiglio, A. (2016). Effects of platelet-rich plasma in  
647 a model of bovine endometrial inflammation *in vitro*. *Reprod Biol Endocrinol* **14**, 58.
- 648 McCallie, B., Schoolcraft, W., Katz-Jaffe, M.G. (2010). Aberration of blastocyst microRNA  
649 expression is associated with human infertility. *Fertil Steril* **93**, 2374-2382.
- 650 Melka, MG, Rings, F., Holker, M., Tholen, E., Havlicek, V., Besenfelder, U., Schellander, K.,  
651 Tesfaye, D. 2010. Expression of apoptosis regulatory genes and incidence of apoptosis in different  
652 morphological quality groups of in vitro produced bovine pre-implantation embryos. *Reprod Domest*  
653 *Anim* **45**, 915-921.
- 654 Mermillod, P., Vansteenbrugge, A., Wils, C., Mourmeaux, J.L., Massip, A., Dessy, F. (1993).  
655 Characterization of the embryotrophic activity of exogenous protein-free oviduct-conditioned  
656 medium used in culture of cattle embryos. *Biol Reprod* **49**, 582-587.
- 657 Park, J.S., Han, Y.M., Lee, C.S., Kim, .SJ., Kim, Y.H., Lee, K.J., Lee, K.S., Lee, K.K. (2000).  
658 Improved development of DNA-injected bovine embryos co-cultured with mouse embryonic  
659 fibroblast cells. *Anim Reprod Sci* **59**, 13-22.
- 660 Pereira, T., Ivanova, G., Caseiro, A.R., Barbosa, P., Bártolo, P.J., Santos, J.D., Luís, A.L., Mauricio,  
661 AC. (2014). MSCs conditioned media and umbilical cord blood plasma metabolomics and  
662 composition. *Plos One* **9**(11), e113769.

- 663 Pohland, R., Tiemann, U. (1994). Immunohistochemical localization of the epidermal growth factor  
664 and its binding sites in the bovine female reproductive tract. *J Reprod Fertil Abstract Series* **14**,  
665 abstract 56.
- 666 Pomar, F.J., Teerds, K.J., Kidson, A., Colenbrander, B., Tharasanit, T., Aguilar, B., Roelen, B.A.  
667 (2005). Differences in the incidence of apoptosis between in vivo and in vitro produced blastocysts  
668 of farm animal species: a comparative study. *Theriogenology* **63**, 2254-2268.
- 669 Raposo, G., Stoorvogel, W. (2013). Extracellular vesicles: exosomes, microvesicles, and friends. *J*  
670 *Cell Biol* **200**, 373-383.
- 671 Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A., Ratajczak, M.Z. (2006).  
672 Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell  
673 communication. *Leukemia* **20**(9), 1487-1495.
- 674 Rexroad Jr, C.E., Powell, A.M. (1993). Development of ovine embryos co-cultured on oviductal  
675 cells, embryonic fibroblasts, or STO cell monolayers. *Biol Reprod* **49**, 789-793.
- 676 Rieger, D., Grisart, B., Semple, E., Van Langendonck, A., Betteridge, K., Dessy, F. (1995).  
677 Comparison of the effects of oviductal cell co-culture and oviductal cell-conditioned medium on the  
678 development and metabolic activity of cattle embryos. *J Reprod Infertil* **105**(1), 91-98.
- 679 Rosenbluth, E.M., Shelton, D.N., Wells, L.M., Sparks, A.E.T, Van Voorhis, B.J. (2014). Human  
680 embryos secrete microRNAs into culture media—a potential biomarker for implantation. *Fertil*  
681 *Steril* **101**, 1493-1500.
- 682 Rottmayer, R., Ulbrich, S., Kölle, S., Prella, K., Neumüller, C., Sinowatz, F., Meyer, H., Wolf, E.,  
683 Hiendleder, S. (2006). A bovine oviduct epithelial cell suspension culture system suitable for  
684 studying embryo-maternal interactions: morphological and functional characterization.  
685 *Reproduction*, **132**, 637-648.
- 686 Schmaltz-Panneau, B., Locatelli, Y., Uzbekova, S., Perreau, C., Mermillod, P. (2015). Bovine  
687 oviduct epithelial cells dedifferentiate partly in culture, while maintaining their ability to improve  
688 early embryo development rate and quality. *Reprod Domest Anim* **50**(5), 719-729.
- 689 Sostaric, E., Dieleman, S.J., van de Lest, C.H., Colenbrander, B., Vos, P.L., Garcia-Gil, N., Gadella,  
690 B.M. (2008). Sperm binding properties and secretory activity of the bovine oviduct immediately  
691 before and after ovulation. *Molec Reprod Develop* **75**, 60-74.

- 692 Thatcher, W.W., Guzeloglu, A., Mattos, R., Binelli, M., Hansen, T.R., Pru, J.K. (2001). Uterine-  
693 conceptus interactions and reproductive failure in cattle. *Theriogenology* **56**, 1435-1450.
- 694 Thery, C., Ostrowski, M., Segura, E. (2009). Membrane vesicles as conveyors of immune  
695 responses. *Nat Rev Immunol* **9**, 581-593.
- 696 Thouas, G.A., Korfiatis, N.A., French, A.J., Jones, G.M., Trounson, A.O. (2001). Simplified  
697 technique for differential staining of inner cell mass and trophectoderm cells of mouse and bovine  
698 blastocysts. *Reprod BioMed Online* **3**, 25-29.
- 699 Ulbrich, S.E., Zitta, K., Hiendleder, S., Wolf, E. (2010). In vitro systems for intercepting early  
700 embryo-maternal cross-talk in the bovine oviduct. *Theriogenology* **73**, 802-816.
- 701 Van Langendonck. A-, Vansteenbrugge. A-, Donnay. I-, Van Soom. A-, Berg. U-, Semple. E-,  
702 Grisart. B-, Mermillod. P-, Brem. G-, Massip. A-, Dessy. F. (1996). Three-year results of in vitro  
703 production of bovine embryos in serum-poor bovine oviduct conditioned medium. An overview.  
704 *Reprod Nutr Dev* **36**, 493-502.
- 705 Van Langendonck, A., Vansteenbrugge, A., Donnay, I., Van Soom, A., Berg, U., Semple, E.,  
706 Grisart, B., Mermillod, P., Brem, G., Massip, A., Dessy, F. (1996). Three-year results of in vitro  
707 production of bovine embryos in serum-poor bovine oviduct conditioned medium. An overview.  
708 *Reprod Nutr Dev* **36**, 493-502.
- 709 Ventura-Junca, P., Irarrázaval, I., Rolle, A.J., Gutiérrez, J.I., Moreno, R.D., Santos, M.J. (2015). In  
710 vitro fertilization (IVF) in mammals: epigenetic and developmental alterations. Scientific and  
711 bioethical implications for IVF in humans. *Biol Res* **48**, 68.
- 712 White, K.L., Hehnke, K., Rickords, L.F., Southern, L.L., Thompson Jr, D.L., Wood, T.C. (1989).  
713 Early embryonic development in vitro by co-culture with oviductal epithelial cells in pigs. *Biol*  
714 *Reprod* **41**, 425-430.
- 715 Wrenzycki, C., Stinshoff, H. (2013). Maturation environment and impact on subsequent  
716 developmental competence of bovine oocytes. *Reprod Domest Anim* **48** (Suppl 1), 38-43.
- 717 Xu, J.S., Cheung, T.M., Chan, S.T.H., Ho, P.C., Yeung, W.S.B. (2001). Temporal effect of human  
718 oviductal cell and its derived embryotrophic factors on mouse embryo development. *Biol Reprod*  
719 **65**, 1481-1488.

- 720 Zhang, M., Ouyang, H., Xia, G. (2009). The signal pathway of gonadotrophins-induced mammalian  
721 oocyte meiotic resumption. *Mol Hum Reprod* **15**, 399-409.
- 722 Zhu, J., Barrat, C.L., Lippes, J., Pacey, A.A., Cooke, I.D. (1994). The sequential effects of human  
723 cervical mucus, oviductal fluid, and follicular fluid on sperm function. *Fertil Steril* **61**, 1129-1135.
- 724 Zquierdo, D., Villamediana, P., Paramio, M.T. (1999). Effect of culture media on embryo  
725 development from prepubertal goat IVM-IVF oocytes. *Theriogenology* **52**, 847-861.
- 726

727 **Table 1: Different experimental conditions of embryo culture and days of supplementation**

728

729

730

731

732

733

734

735

736

737

738

Experimental conditions	days
SOF (CTR)	1
SOF + 20% CM-AMCs	1 or 3 or 5
SOF + 20% SN-AMCs	1 or 3 or 5
SOF + 100x10 <sup>6</sup> MVs-AMCs	1 or 3 or 5
	1 or 3 or 5
SOF + 20% CM-EDCs	
SOF + 20% SN-EDCs	1 or 3 or 5
SOF + 100x10 <sup>6</sup> MVs-EDCs	1 or 3 or 5

Legend: CTR, control; AMCs, amniotic mesenchymal cells; EDCs, endometrial cells; CM, conditioned medium; SN, supernatant; MVs, microvesicles.

**Table 2: Effect of conditioned *medium* (CM) secreted by amniotic or endometrial cells on embryo quality evaluated by differential staining**

Conditioned <i>media</i> (CM)	day	Total cells	Differential staining		
			ICM	TE	Ratio ICM:TE
SOF (CTR)		120.69±5.43	27.6±1.44 <sup>a</sup>	93.09±5.62	29.65±2.03 <sup>a</sup>
SOF + CM-AMCs	1	-	-	-	-
SOF + CM-AMCs	3	115.43±8.82	25.6±2.72 <sup>a</sup>	86.12±4.55	29.75±3.48 <sup>a</sup>
SOF + CM-AMCs	5	128.66±3.52	32.4±1.83 <sup>b</sup>	96.26±5.82	33.66±1.93 <sup>b</sup>
SOF + CM-EDCs	1	-	-	-	-
SOF + CM-EDCs	3	101.66±7.55	20.82±2.98 <sup>c</sup>	76.44±8.37	26.7±5.67 <sup>b</sup>
SOF + CM-EDCs	5	102.91±3.58	25.41±1.03 <sup>a</sup>	87.5±7.54	29.04±2.88 <sup>a</sup>

All values represent mean±standard error

Different small letters superscripts (a,b,c) indicate statistically different comparisons ( $P<0.05$ ).

Legend: CTR, control; AMCs, amniotic mesenchymal cells; EDCs, endometrial cells; ICM, inner cell mass; TE, trophoctoderm cells.

**Table 3: Effect of supernatant (SN) secreted by amniotic or endometrial cells on embryo quality evaluated by differential staining**

Supernatant (SN)	day	Total cells	Differential staining		
			ICM	TE	Ratio ICM:TE
SOF (CTR)		120.69±5.43	27.6±1.44 <sup>a</sup>	93.09±5.62	29.65±2.03 <sup>a</sup>
SOF + SN-AMCs	1	-	-	-	-
SOF + SN-AMCs	3	-	-	-	-
SOF + SN-AMCs	5	105.54±2.51	22.33±2.58 <sup>b</sup>	83.21±5.86	26.84±2.89 <sup>b</sup>
SOF + SN-EDCs	1	-	-	-	-
SOF + SN-EDCs	3	-	-	-	-
SOF + SN-EDCs	5	98.98±2.26	20.29±1.17 <sup>b</sup>	78.69±5.56	25.78±2.83 <sup>b</sup>

All values represent mean±standard error

Different small letters superscripts (a,b,c) indicate statistically different comparisons ( $P<0.05$ ).

Legend: CTR, control, AMCs, amniotic mesenchymal cells; EDCs, endometrial cells; ICM, inner cell mass; TE, trophectoderm cells.

**Table 4: Effect of microvesicles (MVs) secreted by amniotic or endometrial cells on embryo quality evaluated by differential staining**

Microvesicles (MVs)	day	Total cells	Differential staining		
			ICM	TE	Ratio ICM:TE
SOF (CTR)		120.69±5.43	27.6±1.44 <sup>a</sup>	93.09±5.62	29.65±2.03 <sup>a</sup>
SOF + MVs-AMCs	1	108.15±8.49	20.87±1.64 <sup>b</sup>	87.28±3.23	23.91±2.41 <sup>b</sup>
SOF + MVs-AMCs	3	107.83±8.41	25.71±2.16 <sup>a</sup>	82.12±4.37	31.31±3.33 <sup>a</sup>
SOF + MVs-AMCs	5	132.98±8.42	34.42±1.27 <sup>c</sup>	98.56±4.66	34.92±2.98 <sup>c</sup>
SOF + MVs-EDCs	1	115.72±7.55	23.92±2.66 <sup>a</sup>	91.78±3.95	26.06±2.37 <sup>a</sup>
SOF + MVs-EDCs	3	105.77±8.57	20.98±1.14 <sup>b</sup>	84.79±6.12	24.74±2.85 <sup>b</sup>
SOF + MVs-EDCs	5	104.42±7.21	23.18±2.83 <sup>a</sup>	81.22±6.65	28.54±2.51 <sup>a</sup>

All values represent mean±standard error

Different small letters superscripts (a,b,c) indicate statistically different comparisons ( $P<0.05$ ).

Legend: CTR, control; MVs, microvesicles; AMCs, amniotic mesenchymal cells; EDCs, endometrial cells; ICM, inner cell mass; TE, trophectoderm cells.

796 **FIGURE LEGENDS**

797

798 **Figure 1.** Cell morphology. Monolayer of epithelial endometrial (A) and amniotic epithelial cells  
799 (B). Scale bar = 20 $\mu$ m. Original magnification x 20. Immunolocalization of pancytocheratin in  
800 endometrial (C) and amniotic (D) cells. Scale bar = 15  $\mu$ m. Original magnification 40 x.

801

802 **Figure 2.** NanoSight analysis. Results from analysis of MVs purified from endometrial (A) and  
803 amniotic epithelial cells (B). The mean size and particle concentration values were calculated by the  
804 Nanoparticle Tracking Analysis software that allows the analysis of video images of the particle  
805 movement. The curve describes the relationship between particle number distribution (left Y-axis)  
806 and particle size (X-axis).

807

808 **Figure 3.** Incorporation of MVs. Representative micrographs of internalization of MVs labeled with  
809 PKH-26by blastomeres. Under a fluorescent microscope, the blastomeric nuclei are blue (A) and  
810 the MVs are red (B). Representative merged image and z-stack orthogonal projection micrographs  
811 showing the internalization of MVs as detected by confocal microscopy in blastocyst co-cultured  
812 with MVs for 24 h (C). The images were taken at different planes scanned every 5  $\mu$ m from top to  
813 bottom of the blastocyst. Scale bar = 50  $\mu$ m.

814

815 **Figure 4.** Graphic representation of effect of either amniotic or endometrial cell secretomes on  
816 blastocyst formation rate. Different small letter superscripts (a,b,c) indicate statistically different  
817 comparisons ( $P<0.05$ ).

818

819 **Figure 5.** Graphic representation of effect of amniotic or endometrial cell secretomes on embryo  
820 viability. Different small letter superscripts (a,b,c) indicate statistically different comparisons  
821 ( $P<0.05$ ).

822

823 **Figure 6.** Evaluation of blastocyst. Blastocyst at 7 day of culture observed under optical  
824 microscopy (A). Viability staining (B) and differential staining (C) of embryos cultured with  
825 amniotic derived MVs supplemented on day 5. Viability staining (D) and differential staining (E) of  
826 embryos cultured with endometrial derived MVs supplemented on day 5. Scale bar = 50  $\mu\text{m}$ .

827

828 **Figure 7.** Graphic representation of effect of amniotic or endometrial cell secretomes on inner cell  
829 mass. Different small letter superscripts (a,b,c) indicate statistically different comparisons ( $P<0.05$ ).

830

831 **Figure 8.** Quantitative PCR analysis for the expression *BAX* and *GPXI* in blastocysts treated on day  
832 5 with secretomes from both cell lines. Expression levels normalized to the reference gene *GAPDH*.  
833 Data are represented as fold-change compared with expression observed in CTR blastocysts. Values  
834 are mean  $\pm$  SD (n=3). Different letters depict significant ( $P<0.05$ ) differences between treatments.